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ABSTRACT
Objective: Allergic rhinitis (AR) is a heterogeneous disorder characterized by symptoms – sneezing, itching, nasal congestion, and rhinorrhea. The 
aim of the study is to evaluate the efficacy and safety of rupatadine, bilastine, and levocetirizine in AR.
Methods: A prospective, open-label, comparative study was conducted at the Government ENT Hospital, Hyderabad, Telangana. Ninety patients 
diagnosed with AR were randomized, of whom Group 1 received oral tab. bilastine 20 mg once daily, Group 2 received oral tab. levocetirizine 5 mg 
once daily, and Group 3 received oral tab. rupatadine with a dose of 10 mg once daily for 2 weeks. The reduction in total nasal symptom score (TNSS) 
and absolute eosinophil counts (AECs) was compared with baseline and at 2 weeks. Safety was assessed according to adverse events reported during 
the study period. An analysis of variance was used as a test of significance for the three groups.
Results: Overall, 90 cases were included in the study, with 48% of males and 52% of females. All three drugs significantly reduced the TNSS and AEC 
after treatment compared to before treatment (p<0.05). The mean difference in TNSS and AEC showed no statistically significant difference among the 
three groups (TNSS: p>0.908 and AEC: p>0.967). In terms of safety, all three drugs showed nearly similar adverse events.
Conclusion: In this study, after 2 weeks of follow-up, the three drugs (bilastine, levocetirizine, and rupatadine) showed significant improvement 
clinically, but the mean reduction in the score of symptoms and AEC was not statistically significant in the treatment of AR.
Keywords: Allergic rhinitis, Bilastine, Levocetirizine, Rupatadine, Total nasal symptom score, Absolute eosinophil counts.
INTRODUCTION
Allergy is an immune-mediated inflammatory response to common 
environmental allergens that are otherwise harmless [1]. The harmless 
substance is called an “allergen.” Clemens Peter Freiherr von Pirquet, 
an Austrian, and Bela Schick, a Hungarian, are the two pediatricians, 
coined the term “allergy” from the Greek words allos, meaning 
“other” and ergon, meaning “reaction” to describe hypersensitivity 
reactions [2]. Allergic diseases include asthma, rhinitis, anaphylaxis, 
food, drug, or insect allergies. The burden of allergic rhinitis (AR) is 
immense, accounting for 55% of all allergies. AR affects between 20% 
and 30% of all adults [3].
Classification
Allergic and non-allergic are the two main categories of rhinitis. 
Seasonal AR (SAR) is traditionally caused by outdoor allergens such as 
pollen from trees, grass, and weeds. Perennial AR (PAR) patients exhibit 
symptoms year-round and are generally triggered by indoor allergens 
such as pets, dust mite hair, clothing, or pet dander [4].
A major change was the introduction of the terms based on the second 
criterion, that is, duration, AR is classified into intermittent (INT) and 
persistent (PER) types. AR lasting fewer than 4 days/week or less than 
a month per year is referred to as INT AR, and PER AR is the presence of 
symptoms for ≥4 days/week and ≥1 month/year [5].
The treatment regimen for AR includes education of patients, allergen 
and irritant avoidance, pharmacotherapy (all therapeutic options), 
and allergen immunotherapy. Central nervous system (CNS) and 
anticholinergic side effects are associated with the 1st generation 
antihistamines (AHs). In the 1980s, upgraded new-generation AHs in 
terms of safety and efficacy came into the market. For mild SAR and 
PAR, the2nd generation oral AHs are considered first-line treatments [6]. 
This study is intended to compare the efficacy and safety of three 
2nd generation AH drugs, bilastine, levocetirizine, and rupatadine, in AR.
For the treatment of AR, bilastine, a new 2nd generation AH that is potent 
and highly selective for H1 receptors, has been approved. It was first 
approved in the European Union in 2010 and is now available in many 
countries [6]. Bilastine has a good number of the specified attributes 
and meets the criteria for the treatment of AR [7]. Levocetirizine is a 
selective H-1 antagonist and is the R-enantiomer of cetirizine, a potent, 
consistent, and long-lasting medication for the treatment of both INT 
and PER AR, and treatment with levocetirizine 5 mg daily showed a 
significant decrease in symptoms of AR [8].
Rupatadine is a 2nd generation AH against the H1 receptor and also 
has PAF antagonistic activity. Rupatadine has a fast onset of action and 
an increased duration of activation that helped in the improvement of 
symptoms and quality of life (QoL) in patients with AR. Based on its 
anti-inflammatory effect, it improves nasal obstruction, which is most 
disturbing [9].
METHODS
The Institutional Ethics Committee approval was taken. Patients with 
signs and symptoms of AR participated in a randomized, open-labeled, 
prospective, parallel-group study, conducted in the allergy clinic of 
Government E.N.T. Hospital, Koti, Hyderabad, for a duration of 6 months 
from October 2020 to March 2021. The study was registered under 
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Reg. No. ECR/300/Inst/AP/2013/RR-19. The study procedure was 
explained to the participants in their regional language, and written 
informed consent was obtained before the inclusion. If the patient is 
illiterate, a left thumb impression is taken. The diagnosed AR patients 
were screened based on inclusion and exclusion criteria.
Inclusion criteria
1. Age range: 18–55 years
2. Both male and female patients
3. The patient was diagnosed with AR
4. Patients with symptoms for at least 1 month or more clinically
5. Patients willing to give his/her informed consent.
Exclusion criteria
1. >50 years old and over the age of 18
2. Patients with other systemic diseases (cardiac, hepatic, renal failure, 
etc.)
3. Patients with a history of physical findings of nasal pathology
4. Patients with a known history of allergy to study medication
5. Patients who are severely immunocompromised
6. Patients who are on concomitant medications (macrolides, 
antifungals, and steroids), pregnant and lactating women
7. Non-compliant patients.
Amid screening of 100 patients, 90 were enrolled in the study during 
their initial hospital visit and were randomized in a 1:1:1 allocation by 
the simple randomization (odd/even number) method. Each subject 
who fits into the criteria is allocated any one of the study drugs based on 
simple randomization with no masking and grouped into three groups 
each with 30 subjects. The sample size was calculated with standard 
deviation (SD) taken from the previous studies with power as 80% and 
level of significance as 0.05.
Treatment plan
Thirty subjects with AR were divided into three groups: A, B, and C, 
received oral tab. bilastine 20 mg, oral tab. levocetirizine 5 mg, and 
oral tab. rupatadine 10 mg once daily for 2 weeks. The patients were 
advised to take the drugs at the same time every day, 2 h after food at 
bedtime. Medical assessment of each patient was done at baseline and 
2 weeks after treatment based on total nasal symptom score (TNSS) 
and absolute eosinophil count (AEC) levels. The TNSS [10], which 
includes nasal congestion, runny nose, nasal itching, and sneezing, 
was assessed by interviewing the patients and graded according to 
severity.
•	 Grade 0: None – no symptoms
•	 Grade 1: Mild – symptom clearly present but easily tolerated
•	 Grade 2: Moderate – symptom bothersome but tolerable
•	 Grade 3: Severe – symptoms that are difficult to tolerate and interfere 
with activity.
By adding each point of nasal symptoms, the total score of TNSS is 
obtained. The AR is graded depending on the severity and total score 
as mild <6, moderate 6–9, and severe 10–12. The efficacy/treatment 
response was obtained by comparing the investigations and TNSS 
from baseline and at the end of 2 weeks among the three groups. 
Improvement in the scores was considered significant. Clinical safety 
was monitored for treatment-related adverse effects.
The observations and results were tabulated accordingly, and the data 
were analyzed using the Software Package for the Social Sciences. 
Statistical significance among three drugs was evaluated using analysis 
of variance. p≤0.05 was considered statistically significant.
RESULTS
The study comprised a total of 90 AR cases from the allergy clinic of the 
Government ENT Hospital, Hyderabad. Groups A, B, and C treated with 
drugs bilastine, levocetirizine, and rupatadine are given. There are no 
drop-outs and no loss of follow-ups.
The demographic data and clinical profile among the three groups are 
tabulated and compared. Among 90, males were 47 and females were 
43, as shown in Fig. 1 and Table 1. The patients’ age ranges from 18 to 
55 years, as shown in Fig. 2 and Table 2.
In all the three groups, mean TNSS scores reduced significantly after 
treatment compared to before treatment (p<0.05; S). The decrease in 
Table 2: Age distribution of patients among three groups







18–25 7 23.33 9 30.00 5 16.67
26–35 14 46.67 14 46.67 11 36.67
36–45 6 20.00 3 10.00 10 33.33
46–55 3 10.00 4 13.33 4 13.33
30 30 30
Table 1: Gender distribution of patients among three groups
Groups Males Females
Group A 16 14
Group B 15 15






































Fig. 2: Age distribution of patients among three groups
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the TNSS scores is uniform in all the three groups so that there was no 
significant difference in TNSS scores between the groups (p>0.05; NS), 
as shown in Table 3. In all three groups, mean AEC reduced significantly 
after treatment compared to the before treatment (p<0.05; S). The 
decrease in the AEC is uniform in all three groups so that there was 
no significant difference in AEC between the groups (p>0.05; NS), as 
shown in Table 4.
There were no serious adverse events reported in the three groups. 
Mild adverse effects such as dryness of mouth, drowsiness, headache, 
vomiting, and nausea were reported in all the groups and did not 
require hospitalization, dose reduction, or withdrawal of treatment.
DISCUSSION
AR affects 10–40% of individuals worldwide, and it has a substantial 
negative effect on patients’ QoL, sleep, and daily activities. For the 
treatment of patients with AR, fast-acting, effective, non-sedating, and 
modern second-generation oral H1AHs may help subside symptoms [11].
In the present study, three 2nd generation AHs (bilastine, levocetirizine, 
and rupatadine) in AR were compared. As India is a developing country 
with variable income status and people oblivious to purchasing 
treatment medications, the three drugs mentioned in the study, which 
are readily available over the counter, need to be evaluated in terms 
of efficacy and safety. The European Academy of Allergy and Clinical 
Immunology/Allergic Rhinitis and its Impact of Asthma guidelines have 
defined the features that an ideal oral H1 AH should hold. Bilastine 
demonstrates AH and antiallergic properties [12]. A study found that 
rupatadine was better when compared to levocetirizine in the reduction 
of mean TNSS, immunoglobulin E, and AEC [13] and placebo [14]. 
Another study found significant improvement in nasal symptoms with 
bilastine as compared to placebo [15,16]. One clinical trial designed to 
evaluate the efficacy of levocetirizine 5 mg once daily compared with 
placebo demonstrated a greater decrease in TNSS [17]. Bilastine was 
as effective as desloratadine [18] and cetirizine [15] in controlling AR 
symptoms. In patients with AR, levocetirizine proved to have a more 
protective effect when compared to desloratadine and fexofenadine [8]. 
There are numerous studies on AHs in comparison with placebo and 
other 2nd generation AHs, but there are only a few studies in comparison 
of three drugs, especially bilastine, levocetirizine, and rupatadine, 
which are one of the concerns for conducting the present study in AR.
The demographic results in this comparative study show no significant 
difference, reflecting the homogeneity of study patients in three groups. 
A comparison of these three drugs concerning clinical efficacy was 
made based on the effects of TNSS and AEC. The efficacy of the drugs 
assessed clinically revealed improvement symptomatically within 
the groups at the end of the treatment, whereas the mean change in 
TNSS was not statistically significant among the groups. The effect of 
bilastine, levocetirizine, and rupatadine on AEC was also not significant 
(p>0.05).
All three drugs were well tolerated. Reported adverse effects were 
mild and expected, lasted only for a few days, and did not require 
intervention. Serious or new adverse events were not reported. The 
sample size and duration of the study are small, and the study is open 
label due to the non-availability of funds. Further studies are required 
to consider points such as a change in the study population, seasonal 
variation, sample size, and duration of the study.
CONCLUSION
The three drugs bilastine, levocetirizine, and rupatadine were found to 
have more or less similar levels of efficacy in controlling the symptoms 
of AR. The mean change in TNSS was not significant among the three 
groups. The three drugs had no significant difference in the reduction 
of AEC levels. Further studies are required in larger sample size and 
blinding could be considered which can reproduce beneficial outcomes.
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